Fig. 2.
Fig. 2. Cytotoxic lysis of an EBV-transformed lymphoblastoid cell line (LCL), fresh peripheral blood monocytes, or myeloma cell lines by a Vγ2Vδ2 T-cell clone or a Vγ2Vδ2 T-cell line. / Lysis is shown of targets EBV-transformed LCLs (A,B) or fresh peripheral blood monocytes (D, E) or myeloma cell line U266B1 (C) that were either mock-treated (○), pretreated with 10 μM risedronate for 3 hours, and washed 3 times (▪) or were exposed to 10 μM risedronate during assays (●). Effectors were a Vγ2Vδ2 T-cell clone (A,D) or a Vγ2Vδ2 T-cell line (B,C,E).

Cytotoxic lysis of an EBV-transformed lymphoblastoid cell line (LCL), fresh peripheral blood monocytes, or myeloma cell lines by a Vγ2Vδ2 T-cell clone or a Vγ2Vδ2 T-cell line.

Lysis is shown of targets EBV-transformed LCLs (A,B) or fresh peripheral blood monocytes (D, E) or myeloma cell line U266B1 (C) that were either mock-treated (○), pretreated with 10 μM risedronate for 3 hours, and washed 3 times (▪) or were exposed to 10 μM risedronate during assays (●). Effectors were a Vγ2Vδ2 T-cell clone (A,D) or a Vγ2Vδ2 T-cell line (B,C,E).

Close Modal

or Create an Account

Close Modal
Close Modal